<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6593298</article-id><article-id pub-id-type="doi">10.3389/fcvm.2019.00071</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Cytokine Adsorption in Critically Ill Patients Requiring ECMO Support</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lother</surname><given-names>Achim</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/426791/overview"/></contrib><contrib contrib-type="author"><name><surname>Benk</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Staudacher</surname><given-names>Dawid L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Supady</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bode</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wengenmayer</surname><given-names>Tobias</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#8224;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duerschmied</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#8224;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/171115/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center Freiburg University, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Medicine III (Interdisciplinary Medical Intensive Care), Faculty of Medicine, Medical Center, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country></aff><aff id="aff3"><sup>3</sup><institution>Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Cardiovascular Surgery, Heart Center Freiburg University, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Dennis W. T. Nilsen, Stavanger University Hospital, Norway</p></fn><fn fn-type="edited-by"><p>Reviewed by: Naoki Ishimori, Hokkaido University Hospital, Japan; Seitaro Nomura, The University of Tokyo, Japan</p></fn><corresp id="c001">*Correspondence: Daniel Duerschmied <email>daniel.duerschmied@universitaets-herzzentrum.de</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Cardiovascular Metabolism, a section of the journal Frontiers in Cardiovascular Medicine</p></fn><fn fn-type="other" id="fn002"><p>&#8224;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>6</volume><elocation-id>71</elocation-id><history><date date-type="received"><day>13</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#169; 2019 Lother, Benk, Staudacher, Supady, Bode, Wengenmayer and Duerschmied.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Lother, Benk, Staudacher, Supady, Bode, Wengenmayer and Duerschmied</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Systemic inflammation is a key characteristic of sepsis but also also in non-infectious conditions such as post-cardiac arrest syndrome. Cytokine adsorption and extracorporeal membrane oxygenation are emerging therapies applied in these critically ill patients, but the experience with their concurrent use is limited. We evaluated cytokine adsorption in critically ill patients requiring support with either veno-venous (vv) or veno-arterial (va) extracorporeal membrane oxygenation (ECMO) support and hypothesized that adsorber incorporation into the ECMO circuit was technically feasible and not associated with imminent risk. We analyzed data from the first six cases of a prospective single-center registry of patients undergoing veno-venous (vv) or veno-arterial (va) ECMO therapy. While in most published cases cytokine adsorbers were inserted into a hemofiltration circuit, we directly incorporated the adsorber into the ECMO circuit without interruption of continuous ECMO support. We observed no relevant side effects attributable to cytokine adsorption. Thirty-day mortality was 83% (predicted mortality 87%), indicating that the decision for adding cytokine adsorption may have been considered as an ultima ratio decision in severe cases with poor prognosis. Vasopressor or inotrope use, lactate level, and fluid balance did not change significantly when comparing pre- vs. post-cytokine adsorption values. Interestingly, the real-time course of the mentioned three surrogate parameters remained unaltered in all but two cases, regardless of cytokine removal. Beneficial effects of cytokine adsorption are plausible in two va-ECMO-treated patient, where increasing lactate began to drop after initiation of cytokine adsorption. Taken together, these data suggest that incorporation of cytokine adsorption into the management of critically ill patients requiring continued ECMO support is feasible and easy to handle. Whether cytokine removal improves clinical outcome in ECMO-treated patients should now be investigated in randomized controlled trials.</p></abstract><kwd-group><kwd>ECMO</kwd><kwd>cytokine adsorption</kwd><kwd>sepsis</kwd><kwd>inflammation</kwd><kwd>resuscitation</kwd><kwd>cardiac arrest</kwd></kwd-group><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="36"/><page-count count="6"/><word-count count="4147"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Sepsis is one of the leading causes for mortality and persistent impairment world-wide (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>) and new therapeutic approaches are highly needed. A hallmark of sepsis is the systemic inflammatory response. It is characterized by increased release of damage-associated molecular patterns (DAMPs) and unbalanced activation of the innate immune system (<xref rid="B3" ref-type="bibr">3</xref>). Excessive secretion of pro-inflammatory cytokines is considered as one major driver of early mortality in sepsis by mediating capillary leakage and hemodynamic instability (<xref rid="B3" ref-type="bibr">3</xref>). Systemic inflammation occurs also in non-infectious conditions such as post-cardiac arrest syndrome, burn or trauma. Cytokine adsorption has been proposed as a new approach to target systemic inflammation (<xref rid="B3" ref-type="bibr">3</xref>). The CytoSorb hemoadsorption device (CytoSorbents Europe, Berlin, Germany) contains porous polymer beads that adsorb molecules within the 5&#8211;55 kDa range including many cytokines and DAMPs and eliminates them from the circulation (<xref rid="B4" ref-type="bibr">4</xref>&#8211;<xref rid="B6" ref-type="bibr">6</xref>). CytoSorb has already entered clinical application (<xref rid="B7" ref-type="bibr">7</xref>) and randomized clinical trials on sepsis, pancreatitis (clinicaltrials.gov NCT03082469) or heart surgery (clinicaltrials.gov NCT02265419) are ongoing.</p><p>Extracorporeal membrane oxygenation (ECM) is more and more available and used to bridge respiratory or circulatory failure from different causes (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). However, there is only little experience in the application of cytokine adsorption in patients while on ECMO (<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>). Thus, we aimed to evaluate the feasibility of cytokine adsorption in critically ill patients undergoing ECMO therapy.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec><title>Patient Selection</title><p>We present a series of six cases from a single-center registry of patients treated with venovenous (vv) or venoarterial (va) ECMO therapy at the 30-bed medical intensive care unit of the Department of Medicine III (Interdisciplinary Intensive Care), Medical Center, University of Freiburg and Heart Center Freiburg University between July 2015 and April 2017. Data were blinded to patient identity. The study protocol was approved by the local Independent Ethics Committee (Freiburg 151/14) and the study complies with the Declaration of Helsinki.</p></sec><sec><title>Technical Implementation of Cytokine Adsorption During ECMO Therapy</title><p>Cannulation for veno-arterial or veno-venous ECMO was performed in Seldinger's technique bi-femoral or by usage of a double-lumen venous cannula as previously described (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). During ECMO therapy, a CytoSorb hemoadsorption device (CytoSorbents Europe, Berlin, Germany) was integrated into the ECMO circuit (SCPC, Sorin Munich Germany). The CytoSorb adsorber was connected at the arterial oxygenator (EOS ECMO, LivaNova Mirandola, Italy) outlet via an 3-way stop-cock (tube length 50 cm, inner diameter 4.8 mm) and was returned into the venous line before the centrifugal pump (Revolution, LivaNova Mirandola, Italy) (<xref ref-type="fig" rid="F1">Figure 1</xref>) as reported previously (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Blood flow rates through the CytoSorb device were between 150 and 300 ml/min as calculated from blood flow rates before and after return into the venous line (<xref ref-type="fig" rid="F1">Figure 1</xref>). Integration of the adsorber required no or a few seconds halt of the system.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Technical implementation of the cytokine adsorber into the ECMO circuit. The CytoSorb adsorber was connected in parallel, placed at the arterial oxygenator outlet via an 3-way stop-cock and was returned into the venous line before the centrifugal pump. Blood flow was measured before and after the 3-way stop-cock in the venous line.</p></caption><graphic xlink:href="fcvm-06-00071-g0001"/></fig></sec><sec><title>Data Acquisition</title><p>Horowitz index and SOFA score were calculated using onset of ECMO therapy as index event. Norepinephrine, epinephrine, dobutamine and vasopressin were used as vasopressor or inotropic agents, respectively. To allow easier comparison, we derived dose equivalents by dividing the applied dose by the patient's individual maximum dose for each agent. The sum of dose equivalents for all agents used in one case is termed &#8220;adjusted dose equivalent&#8221; in this manuscript (range 0&#8211;4). Vasopressor or inotrope use, fluid balance and plasma lactate levels are given as mean of all available values within 24 h before (pre) or after (post) onset of cytokine adsorption. Laboratory findings are given for the latest measurement before (pre) or within 24 h after (post) onset of cytokine adsorption.</p></sec><sec><title>Statistical Analysis</title><p>Data are presented as mean &#177; SEM and were compared using paired <italic>t</italic>-test with <italic>P</italic> &lt; 0.05 considered to be significant. All statistical analyses were performed using GraphPad Prism 5.04.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>We identified six patients in our registry that received cytokine adsorption while undergoing ECMO therapy for septic shock (<italic>n</italic> = 4) or after cardiac arrest (<italic>n</italic> = 2) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Patient characteristics, laboratory findings and treatment and outcome parameters are outlined in <xref rid="T1" ref-type="table">Table 1</xref>. Mean SOFA score at the time of ECMO onset was 16.3 &#177; 1.2.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Outcome parameters in patients undergoing cytokine adsorption during ECMO therapy. Mean vasopressor or inotropes use <bold>(A)</bold>, mean fluid balance per hour <bold>(B)</bold> and mean arterial lactate concentration as a surrogate parameter of shock <bold>(C)</bold> were determined within 24 h before (pre) and after (post) onset of cytokine adsorption. The time courses of vasopressor or inotropes use <bold>(D)</bold>, fluid balance <bold>(E)</bold> and arterial lactate concentration <bold>(F)</bold> are depicted from 6 h before to 24 h after onset of cytokine adsorption (dashed line). Levels of procalcitonin in septic patients <bold>(G)</bold> or interleukin 6 in patients after cardiac arrest <bold>(H)</bold> were determined during 4 days after onset of cytokine adsorption. Blue circle, case 1; blue square, case 2; blue diamond, case 3; blue triangle, case 4; red circle, case 5; red square, case 6.</p></caption><graphic xlink:href="fcvm-06-00071-g0002"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patient characteristics, laboratory findings and outcome.</p></caption><table-wrap-foot><p><italic>ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; SOFA, sepsis-related organ failure</italic>.</p></table-wrap-foot></table-wrap><p>Cytokine adsorption was initiated early after ECMO onset. CytoSorb&#174;adsorbers were integrated into the extracorporeal circulation without technical difficulties. In three patients, the adsorber was renewed during ECMO therapy. Mean duration of cytokine adsorption in the collective was 29.2 &#177; 8.0 h (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>To determine the therapeutic impact of cytokine removal we measured surrogate parameters of clinical outcome. Cytokine adsorption did not influence the use of vasopressors or inotropes, fluid balance and arterial blood lactate concentrations (<xref ref-type="fig" rid="F2">Figures 2A&#8211;F</xref>) in the total collective. ICU mortality was 83.3% with a mean time to mortality of 10.7 days (<xref rid="T1" ref-type="table">Table 1</xref>). Serum interleukin 6 levels during the course of treatment were available in two cases. Cytokine adsorption lead to a rapid decrease of interleukin 6 by ~85% within the first 24 h of treatment (<xref ref-type="fig" rid="F2">Figures 2G,H</xref>).</p><p>We evaluated potential differences in the effectiveness of cytokine removal for different pathologies. In two patients treated after cardiac arrest we found a decrease in lactate concentration or decelerated increase of cumulative fluid balance, respectively, from approximately 6 h after onset of cytokine removal (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><p>We aimed to assess the safety of cytokine adsorption during ECMO therapy. We did not experience air embolism or hemodynamic or respiratory failure during the technical implementation of the adsorber into the ECMO circuit. Platelet count significantly decreased to 61.2 &#177; 12.5 &#215; 103/&#956;l during the first 24 h of cytokine adsorption (<xref ref-type="fig" rid="F3">Figure 3A</xref>). We found no evidence of altered plasmatic coagulation (<xref ref-type="fig" rid="F3">Figure 3B</xref>). In one case, relevant bleeding occurred during therapy. Of note, this patient had initially presented with marked coagulopathy due to sepsis. In one case, severe infection occurred within days after cytokine adsorption finally leading to fatal septic shock.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Indicators for adverse effects of cytokine adsorption during ECMO therapy. Platelet count <bold>(A)</bold> and international normalized ratio (INR, <bold>B</bold>) were determined before (pre) and after (post) onset of cytokine adsorption. Blue, septic shock; red, cardiac arrest. Blue circle, case 1; blue square, case 2; blue diamond, case 3; blue triangle, case 4; red circle, case 5; red square, case 6.</p></caption><graphic xlink:href="fcvm-06-00071-g0003"/></fig></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>We report here data from six cases in our single center registry on critically ill patients that received cytokine adsorption while undergoing ECMO therapy. We describe a procedure to integrate a cytokine adsorber device into the ECMO circuit. Our data suggest that incorporation of cytokine adsorption during continued ECMO support was feasible.</p><p>Cytokine adsorption has entered clinical application in many intensive care centers and clinicians have provided many patients with this novel treatment option based on an individual, informed or life-threatening urgent treatment decision. Due to the lack of published data from randomized controlled trials, neither indication nor application, duration, or co-treatment have been described in national or international guidelines.</p><p>A number of cases have been reported in which cytokine adsorption has been applied for septic shock (<xref rid="B18" ref-type="bibr">18</xref>&#8211;<xref rid="B20" ref-type="bibr">20</xref>). We have previously observed astonishingly beneficial effects in a patient with severe hemophagocytic lymphohistiocytosis with rapid clinical recovery during cytokine removal (<xref rid="B21" ref-type="bibr">21</xref>). The results obtained from a case series of 26 patients and a recently published prospective trial on 20 patients with septic shock indicate that cytokine adsorption promotes hemodynamic stabilization and lactate clearance (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). We did not observe a significant improval of outcome parameters in septic patients who underwent cytokine adsorption. However, the number of cases included in our study is too low to properly address this point.</p><p>Cytokine adsorption has been used in other states of non-infectious systemic inflammation, including liver transplantation (<xref rid="B24" ref-type="bibr">24</xref>), cardiopulmonary bypass surgery (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>) or cardiogenic shock (<xref rid="B17" ref-type="bibr">17</xref>). We hypothesized that cytokine adsorption might be an effective measure in patients presenting with post-cardiac arrest syndrome. Post-cardiac arrest syndrome is characterized by a severe systemic inflammatory response, which is associated with impaired hemodynamics (<xref rid="B27" ref-type="bibr">27</xref>) and increased mortality (<xref rid="B28" ref-type="bibr">28</xref>). Elevated markers of systemic inflammation such as interleukin 6 drive vascular permeability and leakage (<xref rid="B29" ref-type="bibr">29</xref>), a key characteristic of patients with systemic inflammation (<xref rid="B30" ref-type="bibr">30</xref>), and are predictors of high mortality and poor neurological outcome (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p><p>Capillary leakage leads to impaired tissue perfusion and hypoxia which is reflected by increased serum lactate. In patients undergoing va-ECMO therapy after cardiac arrest or during cardiac shock increased serum lactate is associated with adverse outcome and serial lactate measurements allow to predict mortality (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). In addition, capillary leakage and increased serum lactate frequently trigger a positive fluid balance, which is <italic>per se</italic> associated with poor outcome (<xref rid="B15" ref-type="bibr">15</xref>). It has been suggested that cytokine adsorption restores vascular barrier function (<xref rid="B20" ref-type="bibr">20</xref>) and thus might improve fluid balance and outcome of patients with shock. In two patients who underwent va-ECMO therapy after cardiac arrest, fluid balance and arterial lactate levels markedly lowered from approximately 6 h after onset of cytokine adsorption. This might suggest an additional beneficial effect of cytokine adsorption to va-ECMO therapy during post-cardiac arrest care.</p><p>Usually, cytokine adsorbers are integrated into an extracorporeal hemofiltration circuit (<xref rid="B7" ref-type="bibr">7</xref>). Additional vascular access might be occupied be ECMO cannulas and lead to access-related complications, thus it has been attempted to incorporate cytokine adsorbers into running systems. In patients undergoing cardiac surgery, cytokine adsorbers have been connected to the cardiopulmonary bypass (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Incorporation of the adsorber device into the ECMO circuit as described here is fast and safe and can be easily performed in an intensive care unit setting. This confirms the experiences made at other centers (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Possible complications such as air embolism that may arise from negative pressure in the pre-pump circuit or abnormalities in blood flow were not observed. In a previous study, a similar setup as described here, incorporating chronic renal replacement therapy into an ECMO circuit, has successfully been tested for safety (<xref rid="B16" ref-type="bibr">16</xref>). This approach allows earliest possible initiation of cytokine adsorption in critically ill patients requiring ECMO support. In particular after cardiac arrest this might be a decisive advantage to prevent early onset post-resuscitation syndrome. In addition, it has been suggested that the ECMO itself triggers an inflammatory response due to the exposure of a patient's blood to the non-endothelialised surface of the ECMO circuit (<xref rid="B36" ref-type="bibr">36</xref>) and this might be targetable by cytokine adsorber.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>Taken together, these data suggest that incorporation of cytokine adsorption into the management of critically ill patients requiring continued ECMO support is feasible and easy to handle. Whether cytokine removal improves clinical outcome in ECMO-treated patients after cardiac arrest should be investigated in a prospective clinical trial.</p></sec><sec sec-type="data-availability" id="s6"><title>Data Availability</title><p>The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.</p></sec><sec id="s7"><title>Ethics Statement</title><p>The study protocol was approved by the local Independent Ethics Committee (Freiburg 151/14) and the study complies with the Declaration of Helsinki.</p></sec><sec id="s8"><title>Author Contributions</title><p>AL performed analysis and wrote the manuscript. CBe performed analysis, designed the schematic figure and wrote the manuscript. DS performed analysis and edited the manuscript. AS performed analysis and edited the manuscript. CBo advised conception of the study and edited the manuscript. TW and DD designed the study, analyzed data and wrote the manuscript.</p><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prescott</surname><given-names>HC</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name></person-group>. <article-title>Enhancing recovery from sepsis: a review</article-title>. <source>JAMA</source>. (<year>2018</year>) <volume>319</volume>:<fpage>62</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.17687</pub-id><?supplied-pmid 29297082?><pub-id pub-id-type="pmid">29297082</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source>JAMA</source>. (<year>2016</year>) <volume>315</volume>:<fpage>801</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Scicluna</surname><given-names>BP</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group>
<article-title>The immunopathology of sepsis and potential therapeutic targets</article-title>. <source>Nat Rev Immunol</source>. (<year>2017</year>) <volume>17</volume>:<fpage>407</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.36</pub-id><pub-id pub-id-type="pmid">28436424</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Venkataraman</surname><given-names>R</given-names></name><name><surname>Powner</surname><given-names>D</given-names></name><name><surname>Elder</surname><given-names>M</given-names></name><name><surname>Hergenroeder</surname><given-names>G</given-names></name><name><surname>Carter</surname><given-names>M</given-names></name></person-group>. <article-title>Feasibility study of cytokine removal by hemoadsorption in brain-dead humans</article-title>. <source>Crit Care Med</source>. (<year>2008</year>) <volume>36</volume>:<fpage>268</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1097/01.CCM.0000291646.34815.BB</pub-id><?supplied-pmid 18090355?><pub-id pub-id-type="pmid">18090355</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Venkataraman</surname><given-names>R</given-names></name></person-group>
<article-title>Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia</article-title>. <source>Crit Care Med</source>. (<year>2004</year>) <volume>32</volume>:<fpage>801</fpage>&#8211;<lpage>05</lpage>. <pub-id pub-id-type="doi">10.1097/01.CCM.0000114997.39857.69</pub-id><pub-id pub-id-type="pmid">15090965</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruda</surname><given-names>MC</given-names></name><name><surname>Ruggeberg</surname><given-names>KG</given-names></name><name><surname>O'Sullivan</surname><given-names>P</given-names></name><name><surname>Guliashvili</surname><given-names>T</given-names></name><name><surname>Scheirer</surname><given-names>AR</given-names></name><name><surname>Golobish</surname><given-names>TD</given-names></name><etal/></person-group>. <article-title>Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads</article-title>. <source>PLoS ONE</source>. (<year>2018</year>) <volume>13</volume>:<fpage>e0191676</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0191676</pub-id><?supplied-pmid 29370247?><pub-id pub-id-type="pmid">29370247</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houschyar</surname><given-names>KS</given-names></name><name><surname>Pyles</surname><given-names>MN</given-names></name><name><surname>Rein</surname><given-names>S</given-names></name><name><surname>Nietzschmann</surname><given-names>I</given-names></name><name><surname>Duscher</surname><given-names>D</given-names></name><name><surname>Maan</surname><given-names>ZN</given-names></name><etal/></person-group>. <article-title>Continuous hemoadsorption with a cytokine adsorber during sepsis - a review of the literature</article-title>. <source>Int J Artif Organs</source>. (<year>2017</year>) <volume>40</volume>:<fpage>205</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000591</pub-id><?supplied-pmid 28525674?><pub-id pub-id-type="pmid">28525674</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combes</surname><given-names>A</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Ranieri</surname><given-names>VM</given-names></name></person-group>. <article-title>Fifty years of research in ARDS. Is extracorporeal circulation the future of acute respiratory distress syndrome management?</article-title>
<source>Am J Respir Crit Care Med</source>. (<year>2017</year>) <volume>195</volume>:<fpage>1161</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201701-0217CP</pub-id><?supplied-pmid 28459322?><pub-id pub-id-type="pmid">28459322</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soar</surname><given-names>J</given-names></name><name><surname>Nolan</surname><given-names>JP</given-names></name><name><surname>B&#246;ttiger</surname><given-names>BW</given-names></name><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Lott</surname><given-names>C</given-names></name><name><surname>Carli</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>European Resuscitation Council Guidelines for resuscitation 2015: section 3. Adult advanced life support</article-title>. <source>Resuscitation</source>. (<year>2015</year>) <volume>95</volume>:<fpage>100</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.resuscitation.2015.07.016</pub-id><?supplied-pmid 26477701?><pub-id pub-id-type="pmid">26477701</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marek</surname><given-names>S</given-names></name><name><surname>Gamper</surname><given-names>G</given-names></name><name><surname>Reining</surname><given-names>G</given-names></name><name><surname>Bergmann</surname><given-names>P</given-names></name><name><surname>Mayr</surname><given-names>H</given-names></name><name><surname>Kliegel</surname><given-names>A</given-names></name></person-group>. <article-title>ECMO and cytokine removal for bridging to surgery in a patient with ischemic ventricular septal defect - a case report</article-title>. <source>Int J Artif Organs</source>. (<year>2017</year>) <volume>40</volume>:<fpage>526</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000600</pub-id><?supplied-pmid 28574104?><pub-id pub-id-type="pmid">28574104</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruenger</surname><given-names>F</given-names></name><name><surname>Kizner</surname><given-names>L</given-names></name><name><surname>Weile</surname><given-names>J</given-names></name><name><surname>Morshuis</surname><given-names>M</given-names></name><name><surname>Gummert</surname><given-names>JF</given-names></name></person-group>. <article-title>First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report</article-title>. <source>Int J Artif Organs</source>. (<year>2015</year>) <volume>38</volume>:<fpage>113</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000382</pub-id><?supplied-pmid 25656010?><pub-id pub-id-type="pmid">25656010</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Szigeti</surname><given-names>S</given-names></name><name><surname>Varga</surname><given-names>T</given-names></name><name><surname>Daroczi</surname><given-names>L</given-names></name><name><surname>Barati</surname><given-names>Z</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Continuous cytokine haemoadsorption incorporated into a venoarterial ECMO circuit for the management of postcardiotomy cardiogenic and septic shock - a case report</article-title>. <source>Perfusion.</source> (<year>2018</year>) <volume>33</volume>:<fpage>593</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1177/0267659118777442</pub-id><?supplied-pmid 29779449?><pub-id pub-id-type="pmid">29779449</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>G</given-names></name><name><surname>Hanke</surname><given-names>J</given-names></name><name><surname>Puntigam</surname><given-names>J</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Schmitto</surname><given-names>JD</given-names></name></person-group>
<article-title>Hemoadsorption in cardiac shock with biventricular failure and giant-cell myocarditis: a case report</article-title>. <source>Int J Artif Organs.</source> (<year>2018</year>) <volume>41</volume>:<fpage>474</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/0391398818777362</pub-id><pub-id pub-id-type="pmid">29843541</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trummer</surname><given-names>G</given-names></name><name><surname>Benk</surname><given-names>C</given-names></name><name><surname>Klemm</surname><given-names>R</given-names></name><name><surname>Biever</surname><given-names>P</given-names></name><name><surname>Kalbhenn</surname><given-names>J</given-names></name><name><surname>Schmutz</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Short-term heart and lung support: extracorporeal membrane oxygenation and extracorporeal life support</article-title>. <source>Multimed Man Cardiothorac Surg</source>. (<year>2013</year>) <volume>2013</volume>:<fpage>mmt008</fpage>. <pub-id pub-id-type="doi">10.1093/mmcts/mmt008</pub-id><?supplied-pmid 24413007?><pub-id pub-id-type="pmid">24413007</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staudacher</surname><given-names>DL</given-names></name><name><surname>Gold</surname><given-names>W</given-names></name><name><surname>Biever</surname><given-names>PM</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Wengenmayer</surname><given-names>T</given-names></name></person-group>. <article-title>Early fluid resuscitation and volume therapy in venoarterial extracorporeal membrane oxygenation</article-title>. <source>J Crit Care</source>. (<year>2017</year>) <volume>37</volume>:<fpage>130</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2016.09.017</pub-id><?supplied-pmid 27718412?><pub-id pub-id-type="pmid">27718412</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suga</surname><given-names>N</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>R</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Nakada</surname><given-names>TA</given-names></name><name><surname>Oda</surname><given-names>S</given-names></name></person-group>. <article-title>A safe procedure for connecting a continuous renal replacement therapy device into an extracorporeal membrane oxygenation circuit</article-title>. <source>J Artif Organs</source>. (<year>2017</year>) <volume>20</volume>:<fpage>125</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1007/s10047-017-0952-y</pub-id><?supplied-pmid 28341867?><pub-id pub-id-type="pmid">28341867</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabr&#242;</surname><given-names>MG</given-names></name><name><surname>Febres</surname><given-names>D</given-names></name><name><surname>Recca</surname><given-names>G</given-names></name><name><surname>Lembo</surname><given-names>R</given-names></name><name><surname>Fominskiy</surname><given-names>E</given-names></name><name><surname>Scandroglio</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Blood purification with cytosorb in critically Ill patients: single-center preliminary experience</article-title>. <source>Artif Organs.</source> (<year>2019</year>) <volume>43</volume>:<fpage>189</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/aor.13327</pub-id><?supplied-pmid 30156308?><pub-id pub-id-type="pmid">30156308</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>Recknagel</surname><given-names>P</given-names></name><name><surname>Steltzer</surname><given-names>H</given-names></name></person-group>. <article-title>Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy</article-title>. <source>Int J Artif Organs</source>. (<year>2014</year>) <volume>37</volume>:<fpage>422</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000315</pub-id><?supplied-pmid 24811308?><pub-id pub-id-type="pmid">24811308</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Jauch</surname><given-names>O</given-names></name><name><surname>Noky</surname><given-names>T</given-names></name><name><surname>Friesecke</surname><given-names>S</given-names></name><name><surname>Abel</surname><given-names>P</given-names></name><name><surname>Kaiser</surname><given-names>R</given-names></name></person-group>. <article-title>CytoSorb, a novel therapeutic approach for patients with septic shock: a case report</article-title>. <source>Int J Artif Organs</source>. (<year>2015</year>) <volume>38</volume>:<fpage>461</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000429</pub-id><?supplied-pmid 26349530?><pub-id pub-id-type="pmid">26349530</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>S</given-names></name><name><surname>Thamm</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>BMW</given-names></name><name><surname>Falk</surname><given-names>CS</given-names></name><name><surname>Kielstein</surname><given-names>JT</given-names></name></person-group>. <article-title>Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient</article-title>. <source>J Intensive Care</source>. (<year>2017</year>) <volume>5</volume>:<fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/s40560-017-0208-1</pub-id><?supplied-pmid 28127437?><pub-id pub-id-type="pmid">28127437</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greil</surname><given-names>C</given-names></name><name><surname>Roether</surname><given-names>F</given-names></name><name><surname>La</surname><given-names>Ros&#233;e P</given-names></name><name><surname>Grimbacher</surname><given-names>B</given-names></name><name><surname>Duerschmied</surname><given-names>D</given-names></name><name><surname>Warnatz</surname><given-names>K</given-names></name></person-group>. <article-title>Rescue of cytokine storm due to HLH by hemoadsorption in a CTLA4-deficient patient</article-title>. <source>J Clin Immunol</source>. (<year>2017</year>) <volume>37</volume>:<fpage>273</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-017-0377-7</pub-id><?supplied-pmid 28265964?><pub-id pub-id-type="pmid">28265964</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogelmann</surname><given-names>K</given-names></name><name><surname>Jarczak</surname><given-names>D</given-names></name><name><surname>Scheller</surname><given-names>M</given-names></name><name><surname>Dr&#252;ner</surname><given-names>M</given-names></name></person-group>. <article-title>Hemoadsorption by CytoSorb in septic patients: a case series</article-title>. <source>Crit Care</source>. (<year>2017</year>) <volume>21</volume>:<fpage>74</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-017-1662-9</pub-id><?supplied-pmid 28343448?><pub-id pub-id-type="pmid">28343448</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friesecke</surname><given-names>S</given-names></name><name><surname>Stecher</surname><given-names>SS</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><name><surname>Nierhaus</surname><given-names>A</given-names></name></person-group>. <article-title>Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study</article-title>. <source>J Artif Organs</source>. (<year>2017</year>) <volume>20</volume>:<fpage>252</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10047-017-0967-4</pub-id><?supplied-pmid 28589286?><pub-id pub-id-type="pmid">28589286</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomescu</surname><given-names>DR</given-names></name><name><surname>Olimpia Dima</surname><given-names>S</given-names></name><name><surname>Ungureanu</surname><given-names>D</given-names></name><name><surname>Popescu</surname><given-names>M</given-names></name><name><surname>Tulbure</surname><given-names>D</given-names></name><name><surname>Popescu</surname><given-names>I</given-names></name></person-group>. <article-title>First report of cytokine removal using CytoSorb(R) in severe noninfectious inflammatory syndrome after liver transplantation</article-title>. <source>Int J Artif Organs</source>. (<year>2016</year>) <volume>39</volume>:<fpage>136</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000489</pub-id><?supplied-pmid 27079418?><pub-id pub-id-type="pmid">27079418</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>MH</given-names></name><name><surname>Rinoesl</surname><given-names>H</given-names></name><name><surname>Dragosits</surname><given-names>K</given-names></name><name><surname>Ristl</surname><given-names>R</given-names></name><name><surname>Hoffelner</surname><given-names>F</given-names></name><name><surname>Opfermann</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent</article-title>. <source>Crit Care</source>. (<year>2016</year>) <volume>20</volume>:<fpage>96</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-016-1270-0</pub-id><?supplied-pmid 27059056?><pub-id pub-id-type="pmid">27059056</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tr&#228;ger</surname><given-names>K</given-names></name><name><surname>Fritzler</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Schr&#246;der</surname><given-names>J</given-names></name><name><surname>Skrabal</surname><given-names>C</given-names></name><name><surname>Liebold</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series</article-title>. <source>Int J Artif Organs</source>. (<year>2016</year>) <volume>39</volume>:<fpage>141</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.5301/ijao.5000492</pub-id><?supplied-pmid 27140295?><pub-id pub-id-type="pmid">27140295</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bro-Jeppesen</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>PI</given-names></name><name><surname>Kjaergaard</surname><given-names>J</given-names></name><name><surname>Wanscher</surname><given-names>M</given-names></name><name><surname>Ostrowski</surname><given-names>SR</given-names></name><name><surname>Bjerre</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Level of systemic inflammation and endothelial injury is associated with cardiovascular dysfunction and vasopressor support in post-cardiac arrest patients</article-title>. <source>Resuscitation</source>. (<year>2017</year>) <volume>121</volume>:<fpage>179</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.resuscitation.2017.09.019</pub-id><?supplied-pmid 28947390?><pub-id pub-id-type="pmid">28947390</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bro-Jeppesen</surname><given-names>J</given-names></name><name><surname>Kjaergaard</surname><given-names>J</given-names></name><name><surname>Wanscher</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>N</given-names></name><name><surname>Friberg</surname><given-names>H</given-names></name><name><surname>Bjerre</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Systemic inflammatory response and potential prognostic implications after out-of-hospital cardiac arrest: a substudy of the target temperature management trial</article-title>. <source>Crit Care Med</source>. (<year>2015</year>) <volume>43</volume>:<fpage>1223</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000000937</pub-id><?supplied-pmid 25756419?><pub-id pub-id-type="pmid">25756419</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narazaki</surname><given-names>M</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name></person-group>. <article-title>The two-faced cytokine IL-6 in host defense and diseases</article-title>. <source>Int J Mol Sci</source>. (<year>2018</year>) <volume>19</volume>:<fpage>E3528</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19113528</pub-id><?supplied-pmid 30423923?><pub-id pub-id-type="pmid">30423923</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heradstveit</surname><given-names>BE</given-names></name><name><surname>Guttormsen</surname><given-names>AB</given-names></name><name><surname>Lang&#248;rgen</surname><given-names>J</given-names></name><name><surname>Hammersborg</surname><given-names>SM</given-names></name><name><surname>Wentzel-Larsen</surname><given-names>T</given-names></name><name><surname>Fanebust</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Capillary leakage in post-cardiac arrest survivors during therapeutic hypothermia - a prospective, randomised study</article-title>. <source>Scand J Trauma Resusc Emerg Med.</source> (<year>2010</year>) <volume>18</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.1186/1757-7241-18-29</pub-id><?supplied-pmid 20500876?><pub-id pub-id-type="pmid">20500876</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bro-Jeppesen</surname><given-names>J</given-names></name><name><surname>Kjaergaard</surname><given-names>J</given-names></name><name><surname>Stammet</surname><given-names>P</given-names></name><name><surname>Wise</surname><given-names>MP</given-names></name><name><surname>Hovdenes</surname><given-names>J</given-names></name><name><surname>&#197;neman</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature management at 33 degrees C or 36 degrees C</article-title>. <source>Resuscitation</source>. (<year>2016</year>) <volume>98</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.resuscitation.2015.10.009</pub-id><pub-id pub-id-type="pmid">26525271</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaahersalo</surname><given-names>J</given-names></name><name><surname>Skrifvars</surname><given-names>MB</given-names></name><name><surname>Pulkki</surname><given-names>K</given-names></name><name><surname>Stridsberg</surname><given-names>M</given-names></name><name><surname>R&#248;sj&#248;</surname><given-names>H</given-names></name><name><surname>Hovilehto</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Admission interleukin-6 is associated with post resuscitation organ dysfunction and predicts long-term neurological outcome after out-of-hospital ventricular fibrillation</article-title>. <source>Resuscitation</source>. (<year>2014</year>) <volume>85</volume>:<fpage>1573</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.resuscitation.2014.08.036</pub-id><?supplied-pmid 25238742?><pub-id pub-id-type="pmid">25238742</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slottosch</surname><given-names>I</given-names></name><name><surname>Liakopoulos</surname><given-names>O</given-names></name><name><surname>Kuhn</surname><given-names>E</given-names></name><name><surname>Scherner</surname><given-names>M</given-names></name><name><surname>Deppe</surname><given-names>AC</given-names></name><name><surname>Sabashnikov</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Lactate and lactate clearance as valuable tool to evaluate ECMO therapy in cardiogenic shock</article-title>. (<year>2017</year>) <volume>42</volume>:<fpage>35</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2017.06.022</pub-id><?supplied-pmid 28672145?><pub-id pub-id-type="pmid">28672145</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wengenmayer</surname><given-names>T</given-names></name><name><surname>Duerschmied</surname><given-names>D</given-names></name><name><surname>Graf</surname><given-names>E</given-names></name><name><surname>Chiabudini</surname><given-names>M</given-names></name><name><surname>Benk</surname><given-names>C</given-names></name><name><surname>M&#252;hlschlegel</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Development and validation of a prognostic model for survival in patients treated with venoarterial extracorporeal membrane oxygenation: the PREDICT VA-ECMO score</article-title>. <source>Eur Heart J Acute Cardiovasc Care.</source> (<year>2018</year>) <fpage>2048872618789052</fpage>. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1177/2048872618789052</pub-id><?supplied-pmid 30003795?><pub-id pub-id-type="pmid">30003795</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Kovacs</surname><given-names>E</given-names></name><name><surname>Racz</surname><given-names>K</given-names></name><name><surname>Soltesz</surname><given-names>A</given-names></name><name><surname>Szigeti</surname><given-names>S</given-names></name><name><surname>Kiss</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation - an observational study</article-title>. <source>Clin Transplant.</source> (<year>2018</year>) <volume>32</volume>:<fpage>e13211</fpage>. <pub-id pub-id-type="doi">10.1111/ctr.13211</pub-id><?supplied-pmid 29377282?><pub-id pub-id-type="pmid">29377282</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname><given-names>JE</given-names></name><name><surname>Fanning</surname><given-names>JP</given-names></name><name><surname>McDonald</surname><given-names>CI</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Fraser</surname><given-names>JF</given-names></name></person-group>. <article-title>The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology</article-title>. <source>Crit Care</source>. (<year>2016</year>) <volume>20</volume>:<fpage>387</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-016-1570-4</pub-id><?supplied-pmid 27890016?><pub-id pub-id-type="pmid">27890016</pub-id></mixed-citation></ref></ref-list></back></article>